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AbstrACt
Introduction Nocturnal cough is a burdensome asthma 
symptom. However, knowledge about the prevalence of 
nocturnal cough in asthma is limited. Furthermore, prior 
research has shown that nocturnal cough and impaired 
sleep quality are associated with asthma control, but 
the association between these two symptoms remains 
unclear. This study further investigates the potential of 
these symptoms as markers for asthma control and 
the accuracy of automated, smartphone-based passive 
monitoring for nocturnal cough detection and sleep quality 
assessment.
Methods and analysis The study is a multicentre, 
longitudinal observational study with two stages. Sensor 
and questionnaire data of 94 individuals with asthma will 
be recorded for 28 nights by means of a smartphone. On 
the first and the last study day, a participant’s asthma 
will be clinically assessed, including spirometry and 
fractionated exhaled nitric oxide levels. Asthma control 
will be assessed by the Asthma Control Test and sleep 
quality by means of the Pittsburgh Sleep Quality Index. In 
addition, nocturnal coughs from smartphone microphone 
recordings will be labelled and counted by human 
annotators. Relatively unrestrictive eligibility criteria for 
study participation are set to support external validity of 
study results. Analysis of the first stage is concerned with 
the prevalence and trends of nocturnal cough and the 
accuracies of smartphone-based automated detection of 
nocturnal cough and sleep quality. In the second stage, 
patient-reported asthma control will be predicted in a 
mixed effects regression model with nocturnal cough 
frequencies and sleep quality of past nights as the main 
predictors.
Ethics and dissemination The study was reviewed 
and approved by the ethics commission responsible for 
research involving humans in eastern Switzerland (BASEC 
ID: 2017–01872). All study data will be anonymised on 
study termination. Results will be published in medical and 
technical peer-reviewed journals.
trial registration number NCT03635710; Pre-results.
IntroduCtIon 
Asthma, a chronic respiratory disease, is 
one of the most prevalent chronic condi-
tions. According to the WHO, 235 million 
people suffer from asthma with 383 000 asth-
ma-related deaths in 20151. Common symp-
toms include wheezing, shortness of breath, 
chest tightness and coughing.2 Coughing 
is perceived by patients as a troublesome 
symptom,3 predicts asthma severity4 and indi-
cates a worse prognosis.5
In asthma, coughing and other symp-
toms tend to get worse at night and often 
cause awakenings.2 It has been shown that 
‘asthma control’, the extent to which asthma 
strengths and limitations of this study
 ► The planned study has the potential to generate 
a novel, insightful and externally valid dataset for 
studying nocturnal symptoms in asthma.
 ► Nocturnal cough and sleep quality may be valid 
markers for asthma control, which could help to 
identify windows of opportunities for pharmacologi-
cal and non-pharmacological interventions.
 ► In principle, smartphones are powerful devices for 
the automatic monitoring of asthma symptoms, and 
this study will provide evidence whether symptom 
detection accuracies actually meet clinical require-
ments under real-life conditions.
 ► While the study duration of 29 days per participant 
allows for the investigation of prevalence and trends 
in nocturnal cough and sleep quality, it is not suffi-
cient to account for long-term symptom patterns and 
trends (eg, for seasonal effects in allergic asthma).
 ► Due to the heterogeneity of asthma, the potential 
clinical usefulness of the investigated markers may 
differ considerably between subgroups of individu-
als with asthma.  on
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symptoms are controlled by treatment,2 is statistically asso-
ciated with sleep quality.6 While the association between 
sleep quality and asthma control is well established, the 
role of nocturnal cough is less clear.
A first cross-sectional study has indicated that nocturnal 
cough frequency might be a valid marker for asthma 
control,7 rendering it a potentially useful parameter for 
disease self-monitoring. However, due to the design of the 
above-mentioned study, questions regarding longitudinal 
trends of nocturnal cough in asthma remain unanswered. 
It is also unclear whether nocturnal cough frequency 
holds any value for asthma control prediction. Moreover, 
predictions of asthma control on subsequent days based 
on nocturnal cough frequency could be independent of, 
moderated by or mediated through sleep quality.
The ongoing study addresses these research gaps 
by investigating the prevalence of nocturnal cough in 
asthma over the course of 4 weeks and by exploring the 
interplay of nocturnal cough frequency and sleep quality 
for asthma control levels on subsequent days. In this way, 
the study could indicate whether nocturnal cough and 
sleep quality are useful parameters for signalling windows 
of opportunity during which timely pharmacological and 
non-pharmacological interventions could be adminis-
tered to prevent asthma deteriorations and attacks.
In addition to these medical objectives, the study aims 
to investigate the potential of commercial smartphones 
in the automatic detection of nocturnal cough and assess-
ment of sleep quality. Enabled by the recent progress in 
the domain of machine learning-based symptom detec-
tion,8 9 self-learning algorithms will be applied on the 
study’s smartphone sensor data to develop models for 
detecting and assessing the above-mentioned symptoms. 
The ongoing study explores whether these models are 
sufficiently accurate for potential medical applications.
MEthods And AnAlysIs
The study is designed as a multicentre, longitudinal 
observational study with two stages. The study stages 
are identical in terms of included participants and data 
collection procedure. However, they differ in terms of 
objectives, endpoints and statistical analysis: the first stage 
is mainly concerned with descriptive analysis of nocturnal 
cough, while the second stage focuses on the prediction 
of asthma control based on nocturnal cough frequency 
and sleep quality.
Aims and objectives
The study has three objectives.
Objectives of the first stage
In the first study stage, the prevalence of nocturnal cough 
and trends in nocturnal cough frequency will be explored 
descriptively (1). As a second objective, the study data 
will be used to develop and evaluate machine learning 
models for nocturnal cough detection and sleep quality 
assessment (2).
Objectives of the second stage
In the second stage, the objective is to examine nocturnal 
cough frequency as a marker for asthma control in combi-
nation with sleep quality (3). In other words, the findings 
of Marsden et al7 will be expanded by collecting longitu-
dinal data, adding sleep quality to the prediction model, 
measuring additional outcomes such as asthma quality of 
life and cough status and accounting for environmental 
factors such as weather conditions, pollution and outside 
temperature.
study setting
The study duration per participant will be 29 days with a 
3-day run-in phase from the second to fourth study day. 
Two study centres in Switzerland are participating in the 
ongoing study: the Clinic for Pulmonology and Sleep 
Medicine of the Cantonal Hospital St. Gallen and the 
mediX Group practice Zurich in cooperation with the 
University of Zurich. On the first and last day of the study, 
participants will have an in-person appointment at one 
of the study centres. In the time between appointments, 
patient-reported outcomes and nocturnal sensor data will 
be collected by means of a smartphone.
The first participant was included in February 2018. 
At the time of manuscript submission, 37 participants 
have completed the study. Data collection is expected to 
conclude in the first quarter of 2019.
Eligibility criteria
The population investigated in this study are adults with 
asthma. Inclusion criteria are not restrictive to ensure 
that findings are generalisable to the target population of 
adults with asthma: participants must have self-reported 
physician-diagnosed asthma, be 18 years or older, provide 
written informed consent and know how to operate a 
smartphone (self-reported in a yes–no question).
Participants, to whom the following criteria apply, are 
excluded from participation: participants who are unlikely 
to successfully complete the daily study tasks on a regular 
basis (ie, participants with cognitive impairments due to 
diseases such as severe depression, dementia and Alzhei-
mer’s disease), participants for whom obtaining reliable 
nocturnal measurements is not feasible due to the study’s 
rule-based smartphone recording system (ie, participants 
with severe insomnia and workers with varying day shift 
and night shifts) and participants for whom a solely 
acoustic-based allocation of nocturnal coughs is highly 
error prone (ie, participants who share the bedroom with 
a person from the same sex). For a more differentiated 
rationale behind the latter exclusion criterion, please 
refer to the discussion.
outcomes
An overview of all study measures is presented in table 1 
in the data collection section.
Endpoints of the first stage
The primary endpoint is coughs per night (c/n), obtained 
through smartphone audio-recordings, manually 
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labelled by trained human annotators. Adhering to the 
recommendations of the European Respiratory Society, 
cough is defined in this study as ‘a three-phase expulsive 
motor act characterized by an inspiratory effort (inspi-
ratory phase), followed by a forced expiratory effort 
against a closed glottis (compressive phase) and then 
Table 1 Overview of measures throughout the 29-day study duration
Frame of reference Time of measurement Obtained by
Patient-reported outcomes
Medical questionnaires
  ACT Last 4 weeks d1, d29 Physician*
  ACT Last week† d8, d15, d22, d29 Smartphone app
  PSQI Last 4 weeks d29 Study nurse*
  PSQI Last night† d1 – d29 Smartphone app
  AQ20 Momentary d1, d29 Smartphone app‡ 
  LCQ Last 2 weeks d1, d29 Smartphone app‡
  VAS (severity of nocturnal cough) Last night d1 – d29 Smartphone app
  VAS (severity of cough by day) Last day d1 – d29 Smartphone app
  VAS (asthma symptom strength) This morning d1 – d29 Smartphone app
Other questionnaires
  Usage habit smartphone app Momentary d8, d15, d22, d29 Smartphone app
  Technical evaluation questionnaire Last 4 weeks d29 Study nurse
Medical control questions
  Occurrence of cold/rhinitis Last week d8, d15, d22, d29 Smartphone app
  Asthma related events (exacerbations and physician 
visits)
Last week d8, d15, d22, d29 Smartphone app
Technical control questions
  Smartphone position overnight Last days d3, d14, d24 Smartphone app
  Smartphone distance overnight Last days d3, d14, d24 Smartphone app
Objective measures
Lung function assessments
  FEV1 d1, d29 Spirometry
  FVC d1, d29 Spirometry
  FEV1/FVC d1, d29 Spirometry
  FeNO d1, d29 NIOX handheld device
Smartphone data
  Microphone n1 – n28§ Smartphone app
  Accelerometer n1 – n28§ Smartphone app
  Proximity sensor n1 – n28§ Smartphone app
  Ambient light sensor n1 – n28§ Smartphone app
  GPS n1 – n28§ Smartphone app
  Bluetooth n1 – n28§ Smartphone app
  Usage data (screen lock status, connection status and 
battery status)
n1 – n28§ Smartphone app
*In case of non-resolvable appointment scheduling issues on day 29, the participant is instructed to fill out an online version of the 
questionnaire to ensure parallel measurements between participants.
†The temporal frame of reference for these questionnaires is shortened in comparison with the respective original publication to 
produce more distinct measurements for each participant, thereby increasing the data resolution for statistical modelling. The 
question framing and answer options are adapted to the revised frame of reference.
‡If a participant does not respond to the smartphone app questionnaire in the morning of day 29, the questionnaire will be 
administered by the study nurse during the participant’s study centre visit. 
§n1 is the night between day 1 (d1) and day 2 (d2) and so forth.
ACT, Asthma Control Test; AQ20, Asthma Questionnaire 20; FeNO, fractionated exhaled nitric oxide; FEV1, forced expiratory volume 
in 1 s; FVC, forced vital capacity; GPS, global positioning system; LCQ, Leicester Cough Questionnaire; PSQI, Pittsburgh Sleep 
Quality Index; VAS, visual analogue scale.
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by opening of the glottis and rapid expiratory airflow 
(expulsive phase)’.10
Secondary endpoints are cough-specific health status 
(eg, the presence and severity of cough and its effects 
on quality of life, measured twice by the Leicester Cough 
Questionnaire11 and daily by a visual analogue scale for 
cough severity12) and sleep quality as measured by the 
Pittsburgh Sleep Quality Index (PSQI).13
Endpoints of the second stage
In the second stage, the primary endpoint is patient-re-
ported asthma control measured by the Asthma Control 
Test (ACT).14
The secondary endpoint of this stage is asth-
ma-specific quality of life, as measured by the Asthma 
Questionnaire-20.15
Participant timeline
The study flow chart from a participant’s perspective is 
illustrated in figure 1. Participants have to attend two 
study centre visits at the beginning (d1) and end (d29) of 
the study. Furthermore, participants have to adhere fully 
to the protocol of the smartphone-based remote data 
collection phase (d1–d28) on at least 23 days. Otherwise, 
they will be withdrawn from the study. More specifically, 
participants are instructed to keep the study smartphone 
in their bedroom at night and ensure that the smartphone 
either has a battery level of at least 80% or recharges at 
night. Participants are also asked to complete the daily 
questionnaire (preferably in the morning but before 
21:00 at the latest).
The length of the daily questionnaire differs between 
days. On 21 of 29 days, participants have to answer 13 
questions (approximately 4 min effort). On three occa-
sions, participants will receive 15 questions (d3, d14, d24; 
5 min effort). At the end of each study week, participants 
are asked to fill out an extended questionnaire with 43 
questions (d8, d15, d22; 15 min effort). Most questionnaires 
on the first and last study day will also be administered by 
means of the smartphone (ie, 52 questions on d1 and 62 
questions on d29 with 20 and 25 min effort, respectively). 
Please refer to the data collection section for a detailed 
description of the questionnaire schedule.
sample size
The study is powered with regard to the primary endpoint 
of the second stage. The required sample size was calcu-
lated based on the results of Marsden et al.7 That is, a 
correlation of r=0.30 between nocturnal cough frequency 
and asthma control was set as the expected strength of 
correlation. In order to ensure a power (1-ß) of 80% 
with a two-tailed type 1-error probability (α) of 5% for 
rejecting a zero bivariate correlation,16 85 participants 
Figure 1 Study flow chart from the participant’s perspective. Please note that more detailed information on the assessments 
and measurements is provided in the measures subsection of the data collection section. AC20, Asthma Questionnaire-20; ACT, 
Asthma Control Test; FeNO, fractionated exhaled nitric oxide; LCQ, Leicester Cough Questionnaire; PSQI, Pittsburgh Sleep 
Quality Index; VAS, visual analogue scales).
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are required. In terms of parameter accuracy estima-
tion,17 this sample size would result in a 95% CI for the 
above-mentioned correlation of [0.09, 0.48].
A dropout rate of 10% is assumed, thus 94 participants 
will be recruited. To the best knowledge of the authors, no 
research that investigated the relationship of nocturnal 
cough, sleep quality and asthma control in a longitudinal 
setting is available hitherto. This prohibits a more precise 
evidence-based estimation of the required sample size. 
Consequently, the required sample size calculation does 
not take sleep quality and the longitudinal data structure 
into account. However, due to the comparable strength 
of association between sleep quality and asthma control 
(r=0.31–0.36)6 and nocturnal cough and asthma control 
(r=0.30),7 the required sample size holds for this relation-
ship, too.
recruitment
Personal and impersonal recruitment is employed. 
Eligible participants from the participating study centres 
will be referred directly to the study nurse. Multiple chan-
nels and methods are used for impersonal recruitment: 
emails are sent out to mailing lists from Swiss participant 
organisations for lung diseases and nearby universities, 
flyers are displayed in local medical offices, pharmacies 
and universities and online ads are posted to social media 
websites and digital bulletin boards. Additionally, an 
email is sent out to clients from a Swiss health insurance 
provider who have submitted at least one asthma medica-
tion receipt for reimbursement in the last 6 months. Please 
note that no personal information of any participant will 
be disclosed to the insurance provider. Only aggregated 
data are made available to the insurance provider (eg, the 
presumptive number of clients who have responded to 
mail recruitment).
The recruitment material contains a link to an online 
screening survey, which consists of the participant infor-
mation form, a video introducing the study and a short 
screening questionnaire to test for study eligibility. If 
potential participants state their interest for study partici-
pation and pass the screening survey, their contact details 
are sent to the study nurses for appointment scheduling.
Participants do not receive monetary incentives for 
study participation. However, travelling costs are reim-
bursed up to SFr50 and a lottery will be held on study 
termination, with 10 prizes worth SFr300 each. Further-
more, a personalised summary of patient-reported study 
data is made available to each participant after successful 
study participation.
data collection
Methods
Health professionals will perform medical assessments in 
the study centres on the first and last day of the study. For 
the time between physician appointments, participants 
will be equipped with a smartphone (Samsung Galaxy A3 
2017, SM-A320FL) on which ‘Clara’, the chat-based study 
app, is installed. This app is a study-specific adaption of 
the mobile app18 for the open source behavioural inter-
vention platform MobileCoach ( www. mobile- coach. eu).19 
It records a participant’s sensor data in the night (eg, 
audio data via a smartphone’s microphone) and delivers 
the daily questionnaires to the patients. Figure 2 illus-
trates the app’s user experience. More information on 
the app is provided in the retention section.
Measures
Table 1 summarises the measures including temporal 
framing for patient-reported outcomes, time of measure-
ment and by which means they are obtained (eg, medical 
personnel or by the mobile app). All smartphone 
measures are collected on the study smartphone handed 
out to participants on the first study day. Measures can 
be divided into patient-reported outcomes (eg, medical 
questionnaires) and objective measures (ie, lung func-
tion assessments and nocturnal smartphone sensor data).
Nocturnal smartphone sensor data are recorded by 
default from 23:00 onwards for a recording length of 
9 hours and 40 min to account for the sleeping patterns 
of the general Swiss population (ie, inferring from a 
citizen science study,20 95% of nocturnal sleep sessions 
are shorter than this default recording length). Further-
more, participants can manually start (after 21:00) and 
stop (after 04:00) the sensor data recording, thereby 
overwriting the default recording settings. If a partic-
ipant starts the recording manually after the recording 
has already been started automatically (ie, after 23:00), 
the default recording length is extended so that it encom-
passes 9 hours and 40 min from the moment of manual 
initiation.
In addition to the measures in table 1, a comprehensive 
medical assessment of a participant’s asthma is performed 
on the first study day. The following medical parame-
ters are determined in this assessment: asthma type (eg, 
allergic/non allergic asthma, asthma and obesity), asthma 
history (eg, onset, asthma symptoms and exacerbations in 
the past), asthma severity and control (by means of Global 
Initiative for Asthma (GINA) stage2), asthma medication 
that is prescribed and taken and smoking behaviour. 
The medical assessment on the last study day examines 
whether changes in the above-mentioned parameters 
occurred during the course of the study.
Retention
Adherence to the data collection protocol is promoted 
through multiple strategies. First, participants meet with 
the study nurse during their first study centre visit to 
discuss how they can implement the instructions in their 
daily life and overcome possible barriers. Second, the 
study app contains a reminder system. If participants do 
not interact with the study app (and thus fail to comply 
with their study tasks), they will receive an SMS reminder 
to their private smartphone. If non-adherence occurs for 
two consecutive days, the participant receives a reminder 
phone call from the study nurse. Third, the study app is 
specifically designed to promote participant retention. 
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Participants are guided through the remote data collec-
tion phase of the study by a text-based healthcare chatbot.21 
More specifically, all study information, instructions and 
tasks are conveyed in a daily conversation with ‘Clara’, a 
virtual study nurse designed to establish a working alliance 
with the participant.22 This interactive approach is known 
to increase adherence in clinical settings.23 Furthermore, 
several nudging techniques24 are incorporated in the app 
(figure 2 shows how the study makes use of loss aversion 
in participants to increase engagement, ie, by symbolising 
non-adherence as lost hearts).
data management
All participant data gathered by the physician (eg, results 
of the asthma assessment) and study nurse (eg, lung func-
tion assessments) in the study centres will be transferred 
into an electronic format and stored online on the study 
server. Traceability of changes and version control will 
be managed by the version control software TortoiseSVN 
(https:// tortoisesvn. net/).
Questionnaire data collected by the mobile app will be 
instantly saved on the study server. Nocturnal sensor data 
will be stored locally on the smartphone and backed up 
to external hard drives and secure online storage once a 
participant has completed the study. However, excerpts of 
nocturnal sensor data are uploaded continuously to the 
study server for quality monitoring purposes. ETH Zurich 
provides all study servers and online storage services used 
in the study.
To match different data sources, a unique user hash is 
randomly generated for data obtained by smartphone 
application for each participant, and then linked to the 
participant ID used in the study centres’ case report 
forms. Please note that a participant’s personal infor-
mation is kept exclusively at the study centres in a sepa-
rate document (ie, it is not included in the case report 
forms). Once the data analysis is complete, the docu-
ment containing a participant’s personal information 
is destroyed to anonymise the study data.
Analysis
Data preparation
In order to obtain c/n, which is the primary endpoint of 
the first stage and a fundamental part of the analysis in 
the second stage, the raw audio data have to be annotated 
for cough events. Due to the study setting, human anno-
tators will label cough exclusively based on audio data. 
Every annotator will receive labelling training before 
being granted access to the audio data.
Annotators will be asked to label the explosive phase of 
a cough and, if multiple coughs occur in succession, the 
corresponding cough epoch10 (see figure 3 for an illustra-
tive example for the labelling). By storing the meta-infor-
mation of the cough labels (ie, time at which the cough 
occurred in a given night and cough duration), the time 
spend coughing per night can be calculated (also referred 
to as ‘cough seconds’). In this way, the study’s labelling 
process covers three out of the four ways to quantitatively 
Figure 2 Screenshots of the ‘Clara’ study app. Sidebar for navigation (left), chat-based interface with predefined answer 
options (middle) and questionnaire module for patient-reported outcomes (right).
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describe coughing that are proposed by the European 
Respiratory Society.10
Furthermore, annotators will be asked to label the 
sex of the person for each cough. If uncertainties occur 
during the labelling process (eg, unclear sex of a cougher 
or whether a sound was a cough), annotators will mark 
the corresponding section for review. A subset of the 
recorded nights will be labelled by all annotators, so that 
inter-rater agreement can be estimated.
For subsets of audio data where no human speech 
is included, coughs may be labelled by means of a 
crowdsourcing approach (eg, Amazon Mechanical 
Turk; https://www. mturk. com/).
Planned statistical analysis in the first stage
In the first study stage, c/n will be analysed descriptively 
and visually. Additionally, autoregressive and moving 
average models will be used to model trends in c/n over 
multiple nights.
Additionally, machine-learning models will be devel-
oped to: (1) automatically detect nocturnal cough and 
(2) assess sleep quality based on the smartphone sensor 
data. For (1), manually annotated coughs constitute the 
ground truth and parameters obtained from the smart-
phone audio-recordings serve as algorithm features. 
For (2), PSQI scores are the ground truth and all avail-
able smartphone sensor data may be used as algorithm 
features. Both algorithms will be designed using super-
vised machine learning techniques and evaluated in accor-
dance with standard practice of algorithm development.25
Planned statistical analysis in the second stage
In the second stage, a mixed effects model will be esti-
mated to analyse the diagnostic efficacy of nocturnal 
cough and sleep quality as markers for asthma control 
and asthma-related quality of life. The mixed effects 
model is selected to account for the nested data struc-
ture (ie, c/n is nested in participants). Asthma control, 
as measured by the ACT, will be the predicted outcome. 
In a second model, asthma-related quality of life as 
measured by the AC20 will be used as the outcome vari-
able instead. Predictor variables in both models will be 
c/n, PSQI scores and the interaction of c/n and PSQI 
scores. The models will take multiple control variables 
into account (eg, type of asthma, medication intake, 
concomitant diseases and smoking behaviour). By model-
ling the data with a random intercept and random slope, 
the heterogeneous manifestation of asthma symptoms 
in participants will be represented in the models (eg, 
it seems plausible that c/n might have a higher predic-
tive power for asthma control and/or quality of life for 
some participants; compare cough-variant asthma26). In 
order to account for repeated measurements, the statis-
tical models will rely on an autoregressive covariance 
structure.27
In a further exploratory analysis, a modified version 
of the asthma control mixed effects prediction model 
will estimated in which the outputs of the two machine 
learning models will serve as the predictors instead of 
the corresponding ground truths (ie, manually labelled 
coughs and PSQI scores as described in the last para-
graph). The prediction performance of the original and 
modified model version will be compared so that the 
utility of a machine learning based symptom detection 
approach can be evaluated.
Please note that since the present study is rather explor-
ative in its nature, deviations from the planned statistical 
analysis may be warranted based on the structure and 
distributions of the collected data.
Patient and public involvement
The development of the research objectives was 
informed by two focus groups with adults with asthma. 
The 15 participants were recruited by means of purpo-
sive sampling, ensuring that patients with uncontrolled, 
partially controlled and well-controlled asthma from a 
wide age range (21–66 years) participated in the discus-
sions. Patients voiced the need for a monitoring method 
with objective and unobtrusive symptom measurements. 
Furthermore, passive nocturnal symptom monitoring 
by means of a smartphone was regarded a promising 
approach to satisfy this need.
Figure 3 Labelling example for cough explosive phases and epochs. Screenshot taken in Audacity 2.2.2. (https://www.
audacityteam.org).
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Patients were not directly involved in the design of 
the study. However, insights from the focus groups have 
informed the design of the study app.
Study participants will receive a personalised summary 
of the collected patient-reported study data after 
successful study completion and can opt-in to receive the 
study results once they have been published.
EthICs And dIssEMInAtIon
Consent
Participants will provide informed written consent at 
their first visit of a study centre. Participants can withdraw 
their consent at any time during the study.
Access to data and confidentiality
Only the study team (ie, the study nurses, involved physi-
cians and technical support staff) will have access to the 
study data before anonymisation. Smartphone sensor data 
will be stored separately from private participant informa-
tion obtained in the case report form (CRFs). After the 
study is completed, all participant data will be matched, 
and the physical files containing the private informa-
tion will be destroyed. Furthermore, all audio segments 
containing a participant’s speech will be erased with the 
objective to anonymise all study data. For anonymised 
audio data, the cough labelling process may be scaled by 
means of a crowdsourcing approach.
dissemination policy
Results of the study are planned to be published in 
medical and technical peer-reviewed journals. Consis-
tent with the Open Research Data initiative of the Swiss 
National Science Foundation,28 the study team may 
publish the anonymised study data in a scientific data-
base if participants provide informed consent and all the 
applicable legal provisions are met. CSS insurance, the 
external funder of the study, has no active involvement in 
the study as stated in the funding contracts, for example, 
in terms of study design, data analysis or the decision to 
publish results.
dIsCussIon
The study follows three main objectives: (1) to ascertain 
the prevalence and trends of nocturnal cough in asthma; 
(2) to develop and evaluate smartphone-based machine 
learning models for automated nocturnal cough detec-
tion and sleep quality assessment; and (3) to investigate 
the potential of nocturnal cough frequency as a marker 
for asthma control in combination with sleep quality.
The study is characterised by the volume, variety and 
ecological validity of the collected data. Studies in the 
domain of nocturnal respiratory symptoms are often 
restricted to cross-sectional data,6 7 or only consider 
limited data sources.29 They often rely exclusively on 
survey data30–32 or collect data in artificial settings, such as 
using obtrusive devices for cough detection.33–35 External 
validity is further supported by the modest eligibility 
criteria for study participation: from a medical perspec-
tive, participants are only excluded if they suffer from 
a condition that renders successful study participation 
unlikely. Therefore, study results should be generalisable 
to the general population, which is often not the case in 
asthma-related trials.36
However, external and internal validity constitute 
conflicting priorities in study design.37 The study’s 
emphasis on external validity results in a threat to internal 
validity: in order to enable in situ measurements with a 
high temporal resolution, the study relies considerably 
on patient-reported outcomes and a purely sound-based 
cough annotation approach.
To mitigate constraints of patient-reported outcomes, 
participants will have a run-in phase of 3 days at the begin-
ning of the study, including a training session on the first 
day, when they fill out daily recurring questions under 
supervision of the study nurse.
To enable accurate annotation of coughs, a participant’s 
acoustic fingerprint will be collected on the first study day 
by recording intentional coughs and standardised voice 
samples. Furthermore, participants will indicate every 
morning whether they have slept alone or shared the 
bedroom with another person or a pet. By providing addi-
tional information to human cough annotators, accuracy 
of the labelling process is expected to increase. More-
over, an internal unpublished analysis conducted with 
data from an earlier study38 has indicated that humans 
are able to assign coughs correctly to a person’s sex only 
by means of sound. In this analysis, six annotators, who 
have not received labelling training or information about 
the participants, assigned 53 lab-recorded coughs to the 
correct sex with an average Cohen’s kappa of 0.92 (inter-
pretable as an almost perfect agreement39) after being 
allowed to listen to each cough only once. This finding is 
in line with prior research on sex differences in cough40 41 
and suggests that human annotators are in principle able 
to exploit sex differences in cough sounds to accurately 
match coughs to participants. Therefore, the study’s 
exclusion of participants who share their bedroom with a 
person from the same sex is a further measure to enable 
a reasonably accurate labelling process.
Furthermore, participants regularly specify the smart-
phone’s position and average distance to the bed at night. 
This information serves as a quality control measure for 
the smartphone microphone recordings. By being able to 
reproduce the conditions of seemingly flawed recordings 
(eg, recordings with almost no noise), informed decisions 
can be made post hoc as to whether a participant should 
be withdrawn from the study on grounds of problematic 
recording conditions. However, no such conditions could 
be identified in systematic field tests prior to the study.
limitations
The study constitutes an extensive invasion of a partici-
pant’s privacy and implicitly requires participants to be 
at least partially open to the use of consumer technology 
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for health related matters. Thus, a self-selection bias42 of 
participants can be expected. However, it does not seem 
plausible to assume that attitudes towards study partici-
pation are associated with any aspect of a participant’s 
asthma in a significant way. Therefore, the self-selection 
bias appears to be a negligible limitation for the validity 
of the study. However, the inclusion criterion of self-re-
ported ability to use a smartphone might introduce a 
selection bias affecting the study’s generalisability, espe-
cially due to poorer technology adoption in the elderly.43
A more severe limitation is due to the fact that symptom 
severity in asthma varies over time and is often driven by 
seasonal changes.2 With a duration of 29 days, the proposed 
study does not allow for the investigation of long-term 
within-person symptom trends and patterns. The limited 
study duration also prohibits the prediction of relatively 
rare, but clinically more meaningful outcomes such as 
asthma attacks,36 which occur on average approximately 
once every 2 years per patient.44 For example, a study with 
the objective to predict the risk of an asthma attack in the 
next 30 days considered a period of 18 months45 in order 
to obtain sufficient observations for statistical prediction.
Another important limitation of the study stems from 
the conceptualisation of asthma as a disease. As a recent 
expert commission has argued, asthma is not a homog-
enous, clearly defined disease but instead an umbrella 
term for chronic lung disorders with distinct aetiologies, 
endotypes and phenotypes.36 In this study, self-reported 
physician-diagnosed asthma was defined as the main 
inclusion criterion. Due to this broad and unspecific 
inclusion criterion, the study sample will likely include 
heterogeneous types of asthma. It is conceivable that the 
predictive power of nocturnal cough and sleep quality for 
asthma control may vary significantly between different 
types of asthma and therefore between participants. 
This issue can be addressed statistically by modelling the 
predictive power of nocturnal cough and sleep quality for 
asthma control as random effects. However, a statistical 
solution to a conceptual issue is not a satisfying remedy 
for clinical practice: if the predictive power varies consid-
erably between individual participants, health profes-
sionals would not be able to make an informed decision 
at the point of care whether disease monitoring based on 
nocturnal cough and sleep quality would yield a clinical 
benefit for any given patient. To address this limitation, 
subsequent studies could focus on specific subgroups46 to 
deliver clinically useful predictions: if subgroups can be 
identified for which a robust and consistent prediction 
applies, nocturnal cough and sleep quality could serve as 
valid digital biomarkers in certain subpopulations despite 
the heterogeneity of asthma. However, if the objective of 
subsequent studies is not to enable applicability but to 
ensure generalisability of results, larger sample sizes will 
be required to encompass asthma’s heterogeneity. From 
a technological point of view, the generalisability of the 
machine learning models is constrained due to the fact 
that only one smartphone model is used in this study. 
It is unclear to which extent the accuracy of automated 
nocturnal cough detection and sleep quality assessment 
would vary between smartphones models which, for 
example, differ in terms of built-in sensors,47 recording 
quality and number of microphones.48 Additionally, 
other important factors, such as battery usage49 and 
technological dependence on the smartphone’s oper-
ating system and manufacturer,50 51 need to be addressed 
before the smartphone-based symptom detection models 
could be implemented in clinical practice or in patient 
self-monitoring.
ConClusIon
The proposed longitudinal study investigates the preva-
lence of nocturnal cough in asthma and its potential to 
predict asthma control individually and in combination 
with sleep quality. Although the study design prioritises 
external over internal validity, a selection bias due to poor 
technology adoption in seniors and the limited sample 
size might undermine generalisability. By collecting the 
data with standard smartphones, the study aims to lay the 
groundwork for scalable digital biomarkers for asthma.
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